Y Intercept Hong Kong Ltd Purchases Shares of 102,336 Abeona Therapeutics Inc. $ABEO

Y Intercept Hong Kong Ltd purchased a new position in Abeona Therapeutics Inc. (NASDAQ:ABEO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 102,336 shares of the biopharmaceutical company’s stock, valued at approximately $581,000. Y Intercept Hong Kong Ltd owned approximately 0.20% of Abeona Therapeutics at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Newtyn Management LLC lifted its stake in Abeona Therapeutics by 26.3% during the first quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company’s stock worth $2,285,000 after purchasing an additional 100,000 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Abeona Therapeutics by 49.6% in the first quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock worth $954,000 after purchasing an additional 66,422 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Abeona Therapeutics by 64.1% during the first quarter. Wellington Management Group LLP now owns 153,121 shares of the biopharmaceutical company’s stock valued at $729,000 after buying an additional 59,832 shares during the period. Trexquant Investment LP raised its holdings in Abeona Therapeutics by 74.1% in the 1st quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 50,758 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp lifted its holdings in Abeona Therapeutics by 11.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company’s stock worth $344,000 after buying an additional 7,155 shares during the period. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Trading Down 3.9%

ABEO opened at $4.19 on Friday. Abeona Therapeutics Inc. has a 12 month low of $3.93 and a 12 month high of $7.54. The company has a current ratio of 6.73, a quick ratio of 6.65 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average of $5.63 and a 200 day moving average of $6.01. The firm has a market cap of $214.86 million, a P/E ratio of 5.99 and a beta of 1.45.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $21.71 million. As a group, research analysts forecast that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 24th. Oppenheimer lifted their price target on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a research note on Friday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Monday, October 13th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Abeona Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Insiders Place Their Bets

In related news, SVP Brendan M. O’malley sold 9,366 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $5.39, for a total transaction of $50,482.74. Following the transaction, the senior vice president directly owned 350,763 shares in the company, valued at approximately $1,890,612.57. This represents a 2.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Joseph Walter Vazzano sold 9,035 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $48,698.65. Following the sale, the chief financial officer directly owned 453,631 shares of the company’s stock, valued at $2,445,071.09. This represents a 1.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 63,612 shares of company stock valued at $339,171 over the last three months. 6.90% of the stock is owned by company insiders.

Abeona Therapeutics Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.